Clinical Trials Logo

Common Variable Immunodeficiency clinical trials

View clinical trials related to Common Variable Immunodeficiency.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02960399 Terminated - Clinical trials for X-linked Agammaglobulinemia

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

Start date: December 2015
Phase: N/A
Study type: Interventional

Recommendations concerning the administration of Zostavax® in patients with antibody deficiency are unclear. The investigators plan to assess the immunogenicity and safety of Zostavax® in patients with antibody deficiency as compared with healthy volunteers.

NCT ID: NCT01489618 Terminated - Clinical trials for Common Variable Immunodeficiency

"Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency

EVAD
Start date: June 2009
Phase: Phase 2
Study type: Interventional

The main objective of this study is to evaluate and to compare the specific antibody response to a " prime-boost " vaccine strategy combining the seven valence pneumococcal conjugate vaccine (PnCj) prime at W0 followed by the administration of the pneumococcal capsular polysaccharide vaccine (PPS) boost at W4, to the administration of the pneumococcal capsular polysaccharide vaccine (PPS) alone at W4 in patients with common variable immunodeficiency.

NCT ID: NCT00006054 Terminated - Clinical trials for Graft Versus Host Disease

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Start date: March 2000
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies. II. Determine relevant outcomes of this treatment in these patients including quality of survival, extent of morbidity and mortality from complications of the treatment (e.g., graft versus host disease, regimen related toxicities, B- cell lymphoproliferative disease), and completeness of functional immunoreconstitution.